Status:
COMPLETED
Treatment of Latent Autoimmune Diabetes of the Adult
Lead Sponsor:
Norwegian University of Science and Technology
Conditions:
Diabetes
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle...
Detailed Description
Latent autoimmune diabetes of the adult (LADA) is usually defined as a form of diabetes where the onset of diabetes takes place approximately after 30 years of age, where there is presence of beta-cel...
Eligibility Criteria
Inclusion
- Diabetes diagnosed during 0-3 years before entering the study.
- Age \> or equal to 30 years \< or equal to 75 years
- anti-GAD positivity
- fasting C-peptide \> or equal to 0,3 ng/ml
- no need for insulin treatment by clinical judgement for at least 3 months following the diagnosis of diabetes.
- HbA1c \> 15 % above the upper limit of normal
Exclusion
- Renal insufficiency (plasma creatinine \> 150 mol/L)
- Severe retinopathy (proliferative or pre-proliferative)
- Severe cardiac disease (NYHA III-IV)
- Chronic severe illness judged by the investigator
- Females of reproductive age who wish to become pregnant during the study
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01140438
Start Date
March 1 2009
End Date
November 1 2018
Last Update
January 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valdemar Grill
Trondheim, Norway, 7006